Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Double-crane Pharmaceutical To Increase Production Capacity Of Plastic Bottles For Transfusion

This article was originally published in PharmAsia News

Executive Summary

Double-crane Pharmaceutical plans to invest over 90 million yuan to establish new lines to manufacture plastic bottles for medical transfusion. Parent Double-crane will loan 81.91 and 28.68 million yuan to its wholly-owned subsidiaries in Anhui and Wuhan, respectively. The Anhui base will set up two new and upgrade one transfusion plastic bottle line, while Wuhan will build one new line. When fully operational, the company's transfusion production lines will reach more than 40, with total manufacturing capacity of 1.3 billion bottles/packages. The production will shift toward more plastic packaging, which gives better profit margins. Double-crane Pharmaceutical aims to build up its transfusion business into the top local brand. (Click here for more - Chinese Language)

You may also be interested in...



Amgen’s Mvasi Biosimilar Survives Restraining Order Bid Again

Amgen has an open road for its Mvasi bevacizumab biosimilar after Genentech’s appeal to enjoin sales, over a notice of commercial marketing technicality, was denied. The US firm continues to weigh up patent-infringement proceedings in separate actions.

Generics Industry Experiences Extraordinary First Quarter Due To COVID-19 Crisis

Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.  

Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection

Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.

UsernamePublicRestriction

Register

SC142523

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel